Earnings call transcript: Novacyt H1 2025 revenue rises 18% as margin slips

Novacyt reported first-half revenue of GBP 11.6 million, up 18% year over year, including roughly 9% underlying growth excluding the Southern Cross Diagnostics acquisition. Gross margin fell 1,000bps to 56%, while adjusted EBITDA remained negative at GBP 3.6 million and cash declined to GBP 7.5 million by end-August from GBP 8.9 million at end-June. Management targets GBP 4 million of annualized restructuring savings, with GBP 3.2 million-GBP 3.4 million identified, but expects most benefits from 2027; shares fell 1.68% following the update.

Analysis

ALNOV’s key issue is not top-line momentum but negative incremental economics: additional sales have not translated into gross-profit growth, leaving the operating-loss bridge dependent on cost actions that are largely back-end loaded. On the disclosed operating cash use, the cash cushion appears closer to a 9-12 month runway absent a sharp H2 improvement, working-capital release, or incremental capital; being debt-free does not eliminate dilution risk for a subscale diagnostics company. The decisive 1-3 month datapoint is monthly cash burn after restructuring charges, not revenue growth.

The acquired distribution activity improves APAC channel access but structurally lowers the group’s margin ceiling unless it becomes a vehicle for higher-margin proprietary assays. Likewise, instrument placements are only strategically valuable if they generate recurring assay pull-through; reported instrument demand without installed-base, utilization, and consumables data should be treated as potentially low-quality hardware revenue. The reduction in higher-margin research-use sales is more consequential than the headline growth rate because it raises the revenue threshold required for break-even.

ILMN’s financial exposure is immaterial: the collaboration may validate ALNOV’s technical capabilities, but a framework agreement and initial work order should not be assigned meaningful recurring revenue until contract value, milestone timing, and gross-margin terms are disclosed. Contrarian upside exists if assay adoption and Illumina-funded development convert fixed R&D into externally financed revenue, but the market is right to discount that possibility until cash conversion is visible. This is a binary small-cap execution situation rather than a clean turnaround long.

Key Decisions for Investors

• No immediate ALNOV position for liquid institutional books; treat as a watchlist special situation given likely limited liquidity and a cash-runway/dilution overhang. Reassess after the next cash update or results release if quarterly operating cash burn falls below GBP 1.0 million without relying on asset sales or new equity.
• Set a long ALNOV trigger only if management discloses contracted Illumina work with material revenue value and the company demonstrates two consecutive reporting periods of gross margin above 60%. A move toward EBITDA break-even would support substantial multiple expansion from depressed micro-cap levels; failure to reach those thresholds leaves downside toward financing-value territory.
• For existing ALNOV holders, use any partnership-driven rally to reduce exposure unless accompanied by backlog, assay pull-through, and cash-burn disclosure. Thesis is falsified by cash falling below roughly GBP 4 million before savings materially reduce burn, a new equity raise, or continued erosion in the high-margin research segment.
• Do not alter ILMN exposure on this development. Monitor future statements of work only as a minor indicator of its external-development strategy; the collaboration is too small to affect ILMN earnings, guidance, or valuation.